By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



56 Livingston Avenue

Roseland  New Jersey  07068  U.S.A.
Phone: 800-631-1253 Fax:


Organon creates, manufactures, and markets prescription medicines that improve the health and quality of human life. With approximately 1,800 employees, Organon USA has two corporate locations in the United States. Headquarters are located in Roseland, New Jersey. Organon USA also operates a 174,000-square-foot packaging and distribution center in Allentown, Pennsylvania. On a global level, Organon is headquartered in both Roseland, New Jersey, United States and Oss, the Netherlands. Organon products are sold in more than 100 countries - more than half of which have an Organon subsidiary. Oss, the Netherlands headquarters, is also home to a state-of-the art parenteral production facility. In Cambridge, Massachusetts, Organon maintains a new biotechnology research facility. Another research facility is located in Newhouse, Scotland.

Organon was founded in 1923 and is now a business unit of the healthcare group of Akzo Nobel N.V. Today, Organon has more than 13,000 employees worldwide. Akzo Nobel N.V., based in the Netherlands, serves customers throughout the world with healthcare products, coatings, and chemicals. Organon is the human healthcare business. Intervet is one of the world's top three producers of animal healthcare products. Operating independently under the Organon umbrella is Diosynth, a technology-based manufacturer of active pharmaceutical ingredients for the third-party market. Also included in Akzo Nobel's healthcare group is Nobilon International, a fully integrated biotechnology company that is dedicated to exploring opportunities in the field of human vaccines.

Last Updated: 01-03-2007

Key Statistics

Ownership: Subsidiary

Web Site: Organon
Symbol: AKZOY


Company News
Organon (AKZOY) Takeover Too Costly and Complicated, Says Merck & Co., Inc. (MRK); Merck Plans to Close R&D and Production Line with the Loss of Over 2,000 Jobs 3/7/2011 6:53:36 AM
D-day for Organon (AKZOY) Workers Moves to Wednesday 2/15/2011 6:41:36 AM
Pantarhei to Bid for Merck & Co., Inc. (MRK)'s Organon (AKZOY) Unit 2/14/2011 6:53:28 AM
Ligand Pharmaceuticals Inc. (LGND) and Organon (AKZOY) Mutually Terminate Collaboration and License Agreement 7/31/2009 8:48:14 AM
Schering-Plough Corporation (SGP) Anesthesia Drug Gets Mixed FDA Review 3/10/2008 7:10:08 AM
Schering-Plough Corporation (SGP) Completes $14.43 Billion Acquisition of Organon (AKZOY) 11/19/2007 8:10:07 AM
Study Shows Organon (AKZOY)'s Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 11/14/2007 7:33:08 AM
Organon (AKZOY) Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma 10/30/2007 8:53:14 AM
Organon (AKZOY)'s Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder New Data From a Separate Study Also Show Minimal Effect on Heart Rhythm Changes in Schizophrenia Patients 10/17/2007 8:23:26 AM
Organon (AKZOY) Release: Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 10/16/2007 12:11:35 PM